2021 年第 10 期 第 16 卷

三线及多线应用安罗替尼治疗晚期非小细胞肺癌患者预后的影响因素

Prognostic factors in patients of advanced non-small cell lung cancer treated with third-line and multi-line therapy with anlotinib

作者：杨丽菲1李应龙1陶洁1张园2

英文作者：Yang Lifei1 Li Yinglong1 Tao Jie1 Zhang Yuan2

单位：1新疆医科大学附属肿瘤医院肺内科一病区，乌鲁木齐830000；2新疆医科大学附属肿瘤医院检验科，乌鲁木齐830000

英文单位：1First Ward of Department of Pulmonary Medicine Cancer Hospital Affiliated to Xinjiang Medical University Urumqi 830000 China; 2Department of Clinical Laboratory Cancer Hospital Affiliated to Xinjiang Medical University Urumqi 830000 China

关键词：非小细胞肺癌；安罗替尼；无进展生存期n>新疆医科大学附属肿瘤医院检验科，乌鲁木齐830000

英文关键词：Non-smallcelllungcancer；Anlotinib；Progression-freesurvival

• 摘要：

• 目的  探讨三线及多线应用安罗替尼治疗的晚期非小细胞肺癌(NSCLC)患者预后的影响因素。方法 回顾性分析新疆医科大学附属肿瘤医院2018年6月至2019年5月收治的141例三线及多线治疗中应用安罗替尼的NSCLC患者临床资料。根据患者无进展生存期（PFS）分为PFS＞4个月组（观察组，64例）和≤4个月组（对照组，77例）。比较2组的临床特征，治疗2个周期后癌胚抗原、鳞状细胞癌抗原（SCC）、糖类抗原125降低水平，治疗期间至末次给药后90 d内的不良反应发生率和远期生存率。结果 观察组美国东部肿瘤协作组(ECOG)评分≤2分、病理类型为鳞癌、安罗替尼联合治疗比例［60.9%（39/64）比41.6%(32/77)、46.9%（30/64）比28.6%(22/77)、20.3%（13/64）比6.5%(5/77)］以及治疗2个周期癌胚抗原、SCC、糖类抗原125降低水平均高于对照组（均P＜0.05）。2组各不良反应发生率比较差异均无统计学意义（均P＞0.05）。观察组中位生存时间为11.08个月（95%置信区间：8.27~11.79个月），对照组中位生存时间为5.79个月（95%置信区间：4.39~5.61个月），观察组累积生存率高于对照组（P＜0.05）。结论 ECOG评分>2分、病理类型为腺癌、治疗后肿瘤相关抗原未显著降低、安罗替尼单药治疗可能是三线及多线采用安罗替尼治疗晚期NSCLC患者预后的影响因素。

• Objective To investigate the prognostic factors in patients of advanced non-small cell lung cancer (NSCLC) treated with third-line and multi-line therapy with anlotinib. Methods The clinical data of 141 NSCLC patients admitted to Cancer Hospital Affiliated to Xinjiang Medical University from June 2018 to May 2019 were retrospectively analyzed. All patients were treated with third-line and multi-line therapy with anlotinib. According to the progression-free survival (PFS), patients were divided into PFS>4 months group (observation group, 64 cases) and PFS≤4 months group (control group, 77 cases). The clinical characteristics, the decreased levels of carcinoembryonic antigen, squamous cell carcinoma antigen (SCC) and carbohydrate antigen 125 (CA125) after two cycles of treatment, the incidence of adverse reactions within 90 d after the last administration and long-term survival rate were compared between the two groups. Results The rates of Eastern Cooperative Oncology Group (ECOG) score≤2, pathological type as squamous cell carcinoma, combined treatment with anlotinib ［60.9%(39/64) vs 41.6%(32/77), 46.9%(30/64) vs 28.6%(22/77), 20.3%(13/64) vs 6.5%(5/77)］ and the decreased levels of carcinoembryonic antigen, SCC and CA125 after two cycles of treatment in the observation group were higher than those in the control group (all P<0.05). There were no significant difference in the incidences of adverse reactions (all P>0.05). The median survival time in the observation group was 11.08 months (95% confidence interval: 8.27-11.79 months), and that in the control group was 5.79 months (95% confidence interval: 4.39-5.61 months). The cumulative survival rate in the observation group was higher than that in the control group (P＜0.05）. Conclusions  ECOG score>2, pathological type as adenocaninoma, tumor associated antigen without significant decrease after therapy, and monotherapy with anlotinib may be the prognostic factors of advanced NSCLC patients treated with third-line and multi-line therapy with anlotinib.